Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Reexamination Certificate
2007-01-09
2007-01-09
Huff, Sheela J. (Department: 1643)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
C424S085100, C424S085200, C424S085400, C424S812000, C530S391100, C530S350000, C530S331000, C530S330000, C530S329000, C530S328000, C530S327000, C530S326000, C530S325000, C530S324000
Reexamination Certificate
active
10438502
ABSTRACT:
A liposome composition comprising small, surface-bound effector molecules is disclosed. The liposomes have a surface layer of hydrophilic polymer chains, for enhanced circulation time in the bloodstream. The effector molecules are attached to the distal ends of the polymer chains. In one embodiment, the effector is polymyxin B, for treatment of septic shock.
REFERENCES:
patent: 4179337 (1979-12-01), Davis et al.
patent: 4429008 (1984-01-01), Martin et al.
patent: 4948590 (1990-08-01), Hawrot et al.
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5092885 (1992-03-01), Yamada et al.
patent: 5122614 (1992-06-01), Zalipsky
patent: 5140013 (1992-08-01), Gaudreault et al.
patent: 5149794 (1992-09-01), Yatvin et al.
patent: 5527528 (1996-06-01), Allen et al.
patent: 0 339 504 (1989-11-01), None
patent: 0 428 486 (1991-05-01), None
patent: WO 90/14103 (1990-11-01), None
Abuchowski, A., et al.,J. Biol. Chem. 252(11):3582-3586 (1977).
Berger, H. Jr., and S.V. Pizzo,Blood71(6):1641-1647 (1988).
Blume, G., et al.,Biochimica et Biophysica Acta1149:180-184 (1993).
Cross, et al.,Infect Immun61(7):2741-2747, (1993).
deAzavedo, J.C.S., et al., pp. 419-430 (1985).
Endo, S., et al.,Clinical Therapeutics14(1):64-67 (1992).
Feist, W., et al.,FEMS Microbiology Immunology89:73-90 (1992).
Fitzer-SchillerReuter, G., “Centocor Stops Trials of Flagship Drug”, Washington Post Financial section, pp. D3Jan. 19, 1993.
Harris, et al.,Trends Biotechnol11(2):42-44 (1993).
Hayashi, T., and Y. Ikada,Biotechnology and Polymers(C.G. Gebelein, Ed., Plenum Press, New York), pp. 321-332 (1991).
Hershfield, M.S., et al.,New England J. Med.316(10):589-595 (1987).
Hird,Genes&Cancerpp. 183-189 (1990).
Hunefield, G.,Anaesthesiol Reanimat14(3):131-153 (1989).
Iwamoto, Y., et al.,Science238: 1132-1134 (1987).
Katre, N.V., et al.,Proc. Natl. Acad. Sci. USA84:1487-1491 (1987).
Kawasaki, K., et al.,Biochemical and Biophysical Research Communications174(3):1159-1162 (1991).
Klibanov, A.L., et al.,Am. J. Physiol. Suppl. 261:60-65 (1991).
Klibanov, A.L. and Huang, L.,Journal of Liposome Research2(3):321-334 (1992).
Manson, W.L., et al., Burns 18(2):98-102 (1992).
Maruyama, K., et al.,Proc. Natl. Acad. Sci. USA87:5744-5748 (1990).
Munster, A., et al.,J Burn Care Rehabil10(4);327-330 (1989).
Murata, J., et al.,Int. J. Biol. Macromol. 11:97-99 (1989).
Nitecki, D.E., and L. Aldwin,Biotechnology and Polymers(C.G. Gebelein, Ed., Plenum Press, New York) pp. 295-299 (1991).
Osband, et al.,Imm Today11(6):193-195, (1990).
Saiki, I., et al.,Br. J. Cancer60:722-728 (1989).
Sastry, P.A. et al.,Journal of Bacteriology164(2):571-577 (1985).
Tam, J.P.,Proc. Natl. Acad. Sci. USA85:5409-5413 (1988).
Veronese, F.M., et al.,Applied Biochem. and Biotech. 11:141-149 (1985).
Zalipsky, S., et al.,Eur. Polym. J.19(12):1177-1183 (1983).
Barenholz Yechezkel
Bercovier Herve
Martin Francis J.
Woodle Martin C.
Zalipsky Samuel
ALZA Corporation
Huff Sheela J.
Perkins Coie LLP
LandOfFree
Enhanced circulation effector composition and method does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced circulation effector composition and method, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced circulation effector composition and method will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3798325